This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Astrazeneca Ab. Active years: 2008-2011.
Company Filing History:
Years Active: 2008-2011
Title: Pernilla Sandberg: Innovator in Pharmaceutical Chemistry
Introduction
Pernilla Sandberg is a notable inventor based in Mölndal, Sweden. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 4 patents to her name, her work focuses on addressing critical health issues.
Latest Patents
Among her latest patents is the invention titled "Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators." This invention relates to certain novel compounds that are useful in modulating nuclear hormone receptors, specifically Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2). The compounds have potential applications in treating and preventing various clinical conditions, including cardiovascular diseases such as atherosclerosis, inflammatory diseases, Alzheimer's disease, and lipid disorders. The invention also outlines methods for therapeutic use and pharmaceutical compositions containing these compounds.
Career Highlights
Pernilla Sandberg is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. Her work at AstraZeneca has allowed her to contribute to innovative solutions in healthcare, particularly in the development of therapies for complex diseases.
Collaborations
Throughout her career, Pernilla has collaborated with esteemed colleagues, including Kay Brickmann and Marianne Swanson. These collaborations have further enhanced her research and development efforts in the pharmaceutical industry.
Conclusion
Pernilla Sandberg's contributions to pharmaceutical chemistry and her innovative patents highlight her role as a key inventor in the field. Her work continues to impact the development of therapies for significant health challenges.